Principal Financial Group Inc. Has $2.08 Million Stock Holdings in Amicus Therapeutics, Inc. $FOLD

Principal Financial Group Inc. boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1,229.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 263,325 shares of the biopharmaceutical company’s stock after acquiring an additional 243,519 shares during the quarter. Principal Financial Group Inc. owned 0.09% of Amicus Therapeutics worth $2,075,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its holdings in shares of Amicus Therapeutics by 7.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company’s stock worth $22,061,000 after buying an additional 194,213 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Amicus Therapeutics by 11.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company’s stock worth $8,751,000 after acquiring an additional 113,803 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of Amicus Therapeutics by 37.1% in the first quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company’s stock worth $1,395,000 after acquiring an additional 46,218 shares during the last quarter. Strs Ohio acquired a new stake in shares of Amicus Therapeutics in the 1st quarter valued at approximately $30,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of Amicus Therapeutics by 63.3% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 17,887 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 6,932 shares in the last quarter.

Insiders Place Their Bets

In related news, CEO Bradley L. Campbell sold 75,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the transaction, the chief executive officer owned 1,021,180 shares in the company, valued at $14,613,085.80. The trade was a 6.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ellen Rosenberg sold 23,621 shares of the firm’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $10.00, for a total transaction of $236,210.00. Following the completion of the sale, the insider owned 507,710 shares of the company’s stock, valued at $5,077,100. The trade was a 4.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 394,807 shares of company stock worth $4,486,385. Company insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Zacks Research lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 26th. The Goldman Sachs Group raised their price objective on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Jefferies Financial Group restated a “hold” rating and set a $14.50 price objective (down previously from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. JPMorgan Chase & Co. increased their target price on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, Needham & Company LLC lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 19th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $15.55.

Amicus Therapeutics Trading Down 0.1%

NASDAQ:FOLD opened at $14.30 on Wednesday. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $14.38. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.09 and a current ratio of 2.99. The firm’s fifty day moving average is $13.76 and its 200-day moving average is $10.29. The firm has a market cap of $4.49 billion, a P/E ratio of -357.41 and a beta of 0.38.

Amicus Therapeutics Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.